SUMMARY Patients with cystic fibrosis tend to have reduced serum concentrations of vitamin E and are therefore at risk of developing the neurological complications associated with vitamin E deficiency. Improved survival in cystic fibrosis has resulted in an increasing number of older patients who may develop hepatobiliary complications which may further impair the absorption of vitamin E. In this study the vitamin E status and results of supplementation with oral vitamin E were compared in adult patients with and without evidence of liver involvement as assessed by routine liver function tests. The serum vitamin E concentrations were reduced below normal in 24 of 25 patients. The mean serum vitamin E concentration was significantly lower (p<005) in those patients with abnormal liver function. When vitamin E status was assessed as the serum vitamin E/cholesterol ratio, however, there was no significant difference between those patients with normal and abnormal liver function. After supplementation with oral vitamin E, either 10 mg/kg/day for one month or 200 mg/day (equivalent to 3-4 to 4.4 mg/kg/day) for up to three months, there was no significant difference in the vitamin E status between the two groups. The results of this study indicate that in general, patients with cystic fibrosis and abnormal liver function do not require increased supplements of vitamin E compared with those with normal liver function.
A severe deficiency of vitamin E resulting from prolonged fat malabsorption is a recognised cause of a spinocerebellar disorder comprising areflexia, ataxia, and proprioceptive loss. This syndrome has been described in abetalipoproteinaemial-3 and in children with chronic liver disease.8 It has also been reported in a few cases of adults and children with extensive ileal resection9-10 and patients with cystic fibrosis. 1 13 Reduced serum concentrations of vitamin E have been frequently documented in children and adults with cystic fibrosisl4-7 but the development of overt neurological disease is, relatively rare. In the patients in whom it has been described there have been complications in addition to pancreatic insufficiency which would be expected to further impair absorption of fat and the fat soluble vitamins such as vitamin E. Thus the two patients reported by Elias et Received for publication 9 September 1985 all' had a luminal bile salt concentration which was below the critical micellar concentration and hepatomegaly respectively. The other cases in whom clinical details are available had multiple ileal resections12 or severe liver disease. 13 In a study of 29 unselected patients who had no neurological symptoms one patient had definite reflex and sensory abnormalities and another two were abnormal on neurophysiological grounds.13 Neurological abnormalities were found in 1-5 and 2-5% patients in two other series of patients with cystic fibrosis. 18 Effect ofabnormal liverfunction on vitamin E status and supplementation in adults with cystic fibrosis 717 concentrations decreased from supranormal to normal. They had maintained their large dose of vitamin E (10 mg/kg/day) between the two study periods. In the other patients, with the exception of patient 8, serum vitamin E concentrations tended to rise from a starting level which was around the lower limit of normal. Patient 8 whose serum concentration of vitamin E fell from 12-2 to 6-1 tmol/l after three months on the lower dose of the vitamin had the highest activities of alkaline phosphatase and aspartate transaminase recorded in this study (2900 and 83 IU/l respectively). With this one exception there was no difference in response between those patients with normal and abnormal liver function.
Discussion
The purpose of this study was to determine whether adult patients with cystic fibrosis and evidence of abnormal liver function differed in their vitamin E status and response to supplements of the vitamin compared with similar patients with normal liver function. There has recently been discussion in the literature as to the best way of defining vitamin E deficiency. It has been suggested that serum vitamin E concentrations should be expressed per total lipid or cholesterol concentrations.27-29 In conditions such as cholestatic liver disease serum lipid concentrations tend to be increased and thus a patient with an apparently normal serum vitamin E concentration may have a reduced vitamin E/lipid ratio and possible vitamin E deficiency."9 In our patients, however, serum cholesterol concentrations tended to be reduced and therefore the opposite -that is, a normal ratio with a reduced serum vitamin E concentration, might be expected. In this study vitamin E status was assessed by serum vitamin E concentrations and the serum vitamin E/cholesterol ratio. Using both these indices the majority of patients had vitamin E deficiency. This is in agreement with a number of previous studies in both children and adults1417 with cystic fibrosis. Of the 25 patients studied, only one had a normal serum vitamin E concentration whereas in three the vitamin E/cholesterol ratio was normal.
When the patients were divided according to their liver function tests, the mean serum vitamin E concentration in the patients with abnormal liver function was just significantly lower (p<0-05) than that of patients with normal liver function. A corresponding difference was not, however, apparent when the mean vitamin E/cholesterol ratios were compared. 16 In an earlier study in children with cystic fibrosis we reported that normal serum concentrations of vitamin E could be achieved within one month on a dose of 10 mg/kg/day of the fat soluble preparation of the vitamin. The same dose was therefore, used for a similar period in this study. The majority of the patients (12 out of 15) achieved normal serum concentrations after one month and only one failed to achieve a normal vitamin E/cholesterol ratio. There were no significant differences after supplementation in the mean serum concentrations and ratios between the patients with normal and abnormal liver function. After this dose of 10 mg/kg/day and a period of variable vitamin E intake we observed that a normal vitamin E status could be maintained in all except one patient with a dose of 200 mg/day (equivalent to 3-4-4.4 mg/kg/day). The exception was the patient with the highest activities of alkaline phosphatase and aspartate aminotransferase.
Because of the relationship between severe vitamin E deficiency and neurological dysfunction' and in view of the uncertainty about the degree of vitamin E deficiency required to cause neurological dysfunction, it seems prudent to suggest that where possible serum vitamin E status should be measured in all patients with cystic fibrosis and maintained within normal limits by appropriate supplementation. If it is not possible to regularly monitor serum vitamin E concentrations we would suggest an initial dose of 10 mg/kg/day for at least one month followed by a maintenance dose of 200 mg/day -for example one tablet of Ephynal. This dosage schedule appears to be adequate for all adult patients with the exception of those with grossly abnormal liver function tests. In these latter patients, we would strongly advise that serum vitamin E concentrations are regularly estimated and that the dosage of vitamin E is adjusted accordingly. Such a policy of supplementing deficient patients would be more practical than carrying out regular detailed neurological assessments and starting treatment only when neurological dysfunction becomes clinically evident. It would have the important advantage of preventing neurological disability which may become more prevalent as the population of patients with cystic fibrosis grows older as a result of improved medical management. 
